BioNTech faces several lawsuits in Germany over Covid vaccine side effects

German drug company BioNTech is facing hundreds of lawsuits, worth one million euros, in country for alleged health damage due to its Covid-19 vaccine, co-developed with American pharma giant Pfizer

Covid vaccine, Covid booster
Photo: Bloomberg
IANS New Delhi
2 min read Last Updated : Jun 12 2023 | 3:41 PM IST

German drug company BioNTech is facing hundreds of lawsuits, worth one million euros, in the country for alleged health damage due to its Covid-19 vaccine, co-developed with American pharma giant Pfizer.

While about 224 million Covid vaccine doses were administered in Germany, nearly three-quarters were Pfizer-BioNTech's mRNA jabs, Financial Times reported. BioNTech pioneered the use of messenger RNA in vaccines and shot to fame during the Covid pandemic.

On Monday, the company faces its first lawsuit, in a regional court in Hamburg, filed by a middle-aged medical worker who is seeking 150,000 euros in damages for heart arrhythmia and brain fog which she says were caused after receiving the mRNA jab.

The lawsuit also claims that the mRNA jab caused her upper-body pain, swollen extremities, fatigue, and sleeping disorder.

BioNTech, on its part, claims that the woman has failed to demonstrate a "causal relationship between the adverse events and the vaccine" rather than a coincidental one and described the lawsuit as "without merit", the report said.

Stating that it is confident that the cases would be dismissed, the company said it has also decided not to set aside provisions to cover possible compensation claims.

According to Tobias Ulbrich, a lawyer at Rogert & Ulbrich, one of the law firms representing the claims, blood tests on some of his clients have shown them to be suffering from a "vaccine-acquired immunodeficiency syndrome" or "V-AIDS" -- a syndrome that respected scientists say is not real, the report noted.

"Continuous monitoring of the vaccine's safety profile and after more than 2.6 billion doses of (the Covid-19 vaccine) administered worldwide has to date not identified potential side effects other than those already listed in the respective product information," BioNTech was quoted as saying.

Several peer-reviewed studies have pointed out side effects of Covid-19 vaccinations, neurological complications and an inflammation of the heart known as myocarditis. However, they are rare.

Even if BioNTech gets a verdict which is not in its favour, it is likely to have limited direct financial damage because of a legal shield by the European Union that largely protected vaccine makers from legal liability if they caused unforeseen side effects, the report said.

--IANS

rvt/prw/bg

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :PfizerPharma sectorGermany

First Published: Jun 12 2023 | 3:41 PM IST

Next Story